First I will clarify that I am an ex-holder with a fairly negative view on this company. The announcement came across differently to me. First of all - the rights to a product is different to giving the 'IP outright' remembering that the IP is on the adapt process of treating the tissue. Making pericardium patches in general isn't such a big deal (with the exclusion of the 3D model).
The manufacturing costs + a built in margin will be applied for supplying LMAT. This will cover the COGS incurred. Not sure what the operational / 'corporate' costs incurred as a direct result of the operation in WA but my guess that most of the fat is in the executive/management and sales positions. The sales positions will disappear (recruitment, training, wages) but costs incurred for regulatory/legal, administrative, R&D will be there still...
It'll be interesting to see how this pans out from here on.
- Forums
- ASX - By Stock
- Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular
First I will clarify that I am an ex-holder with a fairly...
-
-
- There are more pages in this discussion • 149 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.15 |
Change
-0.500(3.19%) |
Mkt cap ! $291.2M |
Open | High | Low | Value | Volume |
$15.75 | $15.75 | $15.00 | $294.3K | 19.33K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1135 | $15.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.35 | 88 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1135 | 15.150 |
1 | 40 | 15.110 |
1 | 392 | 15.000 |
1 | 1000 | 14.950 |
2 | 465 | 14.600 |
Price($) | Vol. | No. |
---|---|---|
15.350 | 88 | 1 |
15.500 | 77 | 1 |
15.700 | 277 | 1 |
15.750 | 249 | 1 |
15.880 | 250 | 1 |
Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |